Table 2. Subgroup analysis for OS with positive PD-L1 expression.
| Stratified analysis | No. of studies | No. of patients | Pooled HR (95% CI) | P value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I2 (%) | P value | Model | |||||
| Location | |||||||
| China | 3 | 202 | 1.73 (0.39–7.66) | 0.472 | 78.5 | 0.009 | Random |
| Non-China | 3 | 201 | 1.10 (0.24–5.06) | 0.906 | 81.9 | 0.004 | Random |
| Cut-off value | |||||||
| 5% | 3 | 170 | 4.05 (0.36–45.39) | 0.256 | 87.6 | 0.000 | Random |
| 10% | 2 | 124 | 0.38 (0.18–0.78) | 0.009 | 0.0 | 0.877 | Fixed |
| 32.5% | 1 | 109 | 1.75 (0.93–3.29) | 0.082 | – | – | – |
| PD-L1 antibody company | |||||||
| CST | 3 | 231 | 1.76 (0.36–8.55) | 0.485 | 86.3 | 0.001 | Random |
| Non-CST | 3 | 172 | 1.12 (0.19–6.57) | 0.898 | 82.8 | 0.003 | Random |
OS, overall survival; PD-L1, programmed cell death ligand 1; HR, hazard ratio; CI, confidence interval; CST, Cell Signaling Technology.